vs
INDEPENDENT BANK CORP（INDB）与Ultragenyx Pharmaceutical Inc.（RARE）财务数据对比。点击上方公司名可切换其他公司
INDEPENDENT BANK CORP的季度营收约是Ultragenyx Pharmaceutical Inc.的1.0倍（$212.5M vs $207.3M），INDEPENDENT BANK CORP净利率更高（35.5% vs -62.0%，领先97.5%），INDEPENDENT BANK CORP同比增速更快（46.9% vs 25.9%），INDEPENDENT BANK CORP自由现金流更多（$75.5M vs $-100.8M），过去两年Ultragenyx Pharmaceutical Inc.的营收复合增速更高（38.0% vs 24.3%）
Independent Bank Corp是一家总部位于美国密歇根州大急流城的商业银行，业务全部布局于密歇根州内，目前在全州范围内共设有62家实体营业网点，为当地个人及企业客户提供各类银行金融服务。
Ultragenyx Pharmaceutical Inc.是一家总部位于美国的生物制药企业，专注于研发罕见病和超罕见遗传病的创新治疗方案，这类疾病目前大多无获批疗法，存在大量未被满足的临床需求。公司覆盖生物制剂、小分子药物、基因疗法、反义寡核苷酸及mRNA等多种药物技术平台，研发管线涵盖骨骼、内分泌、代谢、肌肉及中枢神经系统疾病领域。
INDB vs RARE — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $212.5M | $207.3M |
| 净利润 | $75.3M | $-128.6M |
| 毛利率 | — | — |
| 营业利润率 | — | -54.7% |
| 净利率 | 35.5% | -62.0% |
| 营收同比 | 46.9% | 25.9% |
| 净利润同比 | 50.6% | 3.5% |
| 每股收益（稀释后） | $1.51 | $-1.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $212.5M | $207.3M | ||
| Q3 25 | $203.3M | $159.9M | ||
| Q2 25 | $147.5M | $166.5M | ||
| Q1 25 | $145.5M | $139.3M | ||
| Q4 24 | $144.7M | $164.6M | ||
| Q3 24 | $141.7M | $139.5M | ||
| Q2 24 | $137.9M | $147.0M | ||
| Q1 24 | $137.4M | $108.8M |
| Q4 25 | $75.3M | $-128.6M | ||
| Q3 25 | $34.3M | $-180.4M | ||
| Q2 25 | $51.1M | $-115.0M | ||
| Q1 25 | $44.4M | $-151.1M | ||
| Q4 24 | $50.0M | $-133.2M | ||
| Q3 24 | $42.9M | $-133.5M | ||
| Q2 24 | $51.3M | $-131.6M | ||
| Q1 24 | $47.8M | $-170.7M |
| Q4 25 | — | -54.7% | ||
| Q3 25 | 21.8% | -106.9% | ||
| Q2 25 | 44.6% | -64.8% | ||
| Q1 25 | 39.3% | -102.6% | ||
| Q4 24 | — | -74.3% | ||
| Q3 24 | 39.0% | -94.6% | ||
| Q2 24 | 48.1% | -79.1% | ||
| Q1 24 | 45.5% | -151.9% |
| Q4 25 | 35.5% | -62.0% | ||
| Q3 25 | 16.8% | -112.8% | ||
| Q2 25 | 34.6% | -69.0% | ||
| Q1 25 | 30.5% | -108.5% | ||
| Q4 24 | 34.6% | -80.9% | ||
| Q3 24 | 30.3% | -95.7% | ||
| Q2 24 | 37.2% | -89.5% | ||
| Q1 24 | 34.8% | -156.8% |
| Q4 25 | $1.51 | $-1.28 | ||
| Q3 25 | $0.69 | $-1.81 | ||
| Q2 25 | $1.20 | $-1.17 | ||
| Q1 25 | $1.04 | $-1.57 | ||
| Q4 24 | $1.18 | $-1.34 | ||
| Q3 24 | $1.01 | $-1.40 | ||
| Q2 24 | $1.21 | $-1.52 | ||
| Q1 24 | $1.12 | $-2.03 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $421.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $3.6B | $-80.0M |
| 总资产 | $24.9B | $1.5B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
| Q4 25 | — | $421.0M | ||
| Q3 25 | — | $202.5M | ||
| Q2 25 | — | $176.3M | ||
| Q1 25 | — | $127.1M | ||
| Q4 24 | — | $174.0M | ||
| Q3 24 | — | $150.6M | ||
| Q2 24 | — | $480.7M | ||
| Q1 24 | — | $112.3M |
| Q4 25 | $3.6B | $-80.0M | ||
| Q3 25 | $3.5B | $9.2M | ||
| Q2 25 | $3.1B | $151.3M | ||
| Q1 25 | $3.0B | $144.2M | ||
| Q4 24 | $3.0B | $255.0M | ||
| Q3 24 | $3.0B | $346.8M | ||
| Q2 24 | $2.9B | $432.4M | ||
| Q1 24 | $2.9B | $140.3M |
| Q4 25 | $24.9B | $1.5B | ||
| Q3 25 | $25.0B | $1.2B | ||
| Q2 25 | $20.0B | $1.3B | ||
| Q1 25 | $19.9B | $1.3B | ||
| Q4 24 | $19.4B | $1.5B | ||
| Q3 24 | $19.4B | $1.5B | ||
| Q2 24 | $19.4B | $1.6B | ||
| Q1 24 | $19.3B | $1.3B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $78.9M | $-99.8M |
| 自由现金流经营现金流 - 资本支出 | $75.5M | $-100.8M |
| 自由现金流率自由现金流/营收 | 35.5% | -48.6% |
| 资本支出强度资本支出/营收 | 1.6% | 0.5% |
| 现金转化率经营现金流/净利润 | 1.05× | — |
| 过去12个月自由现金流最近4个季度 | $239.0M | $-472.0M |
8季度趋势，按日历期对齐
| Q4 25 | $78.9M | $-99.8M | ||
| Q3 25 | $52.2M | $-91.4M | ||
| Q2 25 | $106.7M | $-108.3M | ||
| Q1 25 | $13.3M | $-166.5M | ||
| Q4 24 | $42.9M | $-79.3M | ||
| Q3 24 | $70.2M | $-67.0M | ||
| Q2 24 | $65.6M | $-77.0M | ||
| Q1 24 | $51.1M | $-190.7M |
| Q4 25 | $75.5M | $-100.8M | ||
| Q3 25 | $49.7M | $-92.7M | ||
| Q2 25 | $102.5M | $-110.7M | ||
| Q1 25 | $11.3M | $-167.8M | ||
| Q4 24 | $36.5M | $-79.5M | ||
| Q3 24 | $64.4M | $-68.6M | ||
| Q2 24 | $61.9M | $-79.0M | ||
| Q1 24 | $46.7M | $-193.9M |
| Q4 25 | 35.5% | -48.6% | ||
| Q3 25 | 24.4% | -58.0% | ||
| Q2 25 | 69.5% | -66.5% | ||
| Q1 25 | 7.8% | -120.5% | ||
| Q4 24 | 25.2% | -48.3% | ||
| Q3 24 | 45.4% | -49.2% | ||
| Q2 24 | 44.9% | -53.7% | ||
| Q1 24 | 34.0% | -178.2% |
| Q4 25 | 1.6% | 0.5% | ||
| Q3 25 | 1.2% | 0.8% | ||
| Q2 25 | 2.9% | 1.5% | ||
| Q1 25 | 1.4% | 1.0% | ||
| Q4 24 | 4.4% | 0.1% | ||
| Q3 24 | 4.1% | 1.2% | ||
| Q2 24 | 2.7% | 1.4% | ||
| Q1 24 | 3.2% | 3.0% |
| Q4 25 | 1.05× | — | ||
| Q3 25 | 1.52× | — | ||
| Q2 25 | 2.09× | — | ||
| Q1 25 | 0.30× | — | ||
| Q4 24 | 0.86× | — | ||
| Q3 24 | 1.64× | — | ||
| Q2 24 | 1.28× | — | ||
| Q1 24 | 1.07× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
INDB
暂无分部数据
RARE
| Royalty | $105.6M | 51% |
| Products | $101.7M | 49% |
